{
  "L103": [
    {
      "page": 4,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Lecture Content Guide\n\u2022 Red text on slides = know for exams.\n\u2022 Anatomical structures labeled in red or red highlight = know \nfor exams. Note: other structures may still be tested on \nanatomy exam (consult the lab checklist).\n\u2022\n Clinical Correlates\n = know for exams.\n\u2022 Go over Learning Objectives in the CPG..."
    },
    {
      "page": 22,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Source: Anatomy-Medicine\nClinical Correlate\n  \u201cDanger Zone\u201d #1 (of 3)\nPterion: junction of frontal, parietal, \ntemporal, sphenoid bones; thin area \noverlying middle meningeal a...."
    },
    {
      "page": 23,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Source: Anatomy-Medicine; Neurosurgical Atlas\nPterion: junction of frontal, parietal, \ntemporal, sphenoid bones; thin area \noverlying middle meningeal a.\nClinical Correlate\n  \u201cDanger Zone\u201d #1 (of 3)\nHard blow to side \nof the head may \nfracture thin \nbones forming the \npterion, rupturing \nthe middle \nmeningeal a. \nwhich sits \nbetween the skull \nand dura mater...."
    },
    {
      "page": 24,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n  \u201cDanger Zone\u201d #1 (of 3)\nTypes of Intracranial Hemorrhage/Hematoma Intracranial hemorrhage/hematoma: \nBlood accumulation in the endocranial \n(brain) cavity, resulting in life \nthreatening compression of the brain. \n1. Epidural hematoma: between skull \nand dura mater. \n2. Subdural hematoma: between \ndura mater and arachnoid mater. \nCommon when bridging veins and \nsagittal sinus is torn.\n3. Subarachnoid hemorrhage: \nbetween arachnoid mater and pia \nmater. Common when cerebral \n..."
    },
    {
      "page": 27,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n \u201cDanger Zone\u201d #2 (of 3)\nSource: Lachkar et al. 2019\nFacial vein has no valves, so \nblood may drain superiorly into \nsuperior & inferior ophthalmic \nveins and enter the cavernous \nsinus.\nInfection around the nose (e.g., \npimples, boils) can spread into \ncavernous sinus where important \narteries and nerves are located...."
    },
    {
      "page": 28,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n \u201cDanger Zone\u201d #2 (of 3)\nSource: Lachkar et al. 2019\n..."
    },
    {
      "page": 30,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n \u201cDanger Space\u201d #3 (of 3)\nInvesting Fascia\nDanger Zone: space between \nalar fascia and prevertebral \nfascia. Infections can travel \ndown through mediastinum to \ndiaphragm\nSource: Netter\u2019s Anatomical Atlas\ninvesting fascia\npretracheal fascia\ncarotid sheath\nprevertebral fascia\nalar fascia..."
    },
    {
      "page": 38,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n Thyroid Gland Diseases\nGoiter: enlargement of the thyroid gland, \npresented as lump on anterior aspect of the \nneck. Often due to iodine deficiency. Could \nbe associated with:\nHyperthyroidism: overproduction of \nthyroid hormones.\nHypothyroidism: underproduction of \nthyroid hormones. Glands swell to try to \nproduce more hormones.\nCould cause breathing/swallowing \ndifficulties or speech loss due to \ncompression of the trachea, larynx, \nesophagus, recurrent laryngeal nerve.\nSour..."
    },
    {
      "page": 59,
      "keywords": [
        "clinical correlate"
      ],
      "text": "\u201cHigh-Yield\u201d Topics\n\u2022 Anatomical organization of the skeletal, nervous, vascular, digestive, and \nrespiratory systems in the head and neck; and how these change from \nnewborns to adult.\n\u2022 The three \u201cDanger Zones\u201d in the head and neck and how they\u2019re \ndangerous.\n\u2022 Locations and functions of organs that only exist in the head and neck, \nsuch as glands.\n\u2022 Names, fiber types, and functions of each cranial nerve.\n\u2022 Clinical correlates...."
    }
  ],
  "L104": [
    {
      "page": 2,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Lecture Content Guide\n\u2022 Red text on slides = know for exams.\n\u2022 Anatomical structures labeled in red or red highlight = know for \nexams. Note: other structures may still be tested on anatomy \nexam (consult the lab checklist).\n\u2022\n Clinical Correlates\n = know for exams.\n\u2022 Go over Learning Objectives in the CPG..."
    },
    {
      "page": 41,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlates\n  Branchial Fistula & Cyst\nSource: 78stepheath.us; Univ. of Iowa Carver College of Medicine\n\u2022 Caused by persistent cervical sinus derived from fusion of Pharyngeal Clefts 2\u20134.\n\u2022 Typically, internal fistula opens at the palatine tonsil formed from Pouch 2 and \nexternal fistula opens on the skin of the neck anterior to the sternocleidomastoid m. ..."
    },
    {
      "page": 50,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Source: The Developing Human: Clinically Oriented Embryology 9e\nClinical Correlate\n  Thyroglossal Duct Cyst, Sinus; Pyramidal Lobe\nThyroglossal Duct Sinus Thyroglossal Duct Cyst Ectopic Thyroid Gland\n\u2022 Thyroglossal duct cyst forms in the midline (not lateral) of the neck from incomplete closure of the thyroglossal \nduct. Rupture of this cyst from infection, creates a sinus. \n\u2022 Ectopic thyroid gland is the existence of gland tissue along the path of the thyroglossal duct (common)...."
    },
    {
      "page": 54,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n  Cleft Lip, Cleft Palate\nSource: ScienceDirect\nThe palate forms through two stages\n\u2022 Primary palate: extension of the intermaxillary segment from the nasal prominences.\n\u2022 Secondary palate: joining of the palatine process from the maxillary prominences...."
    },
    {
      "page": 55,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Source: ScienceDirect; The Developing Human: Clinically Oriented Embryology 9e \nCleft Lip & Palate: caused by incomplete \nclosure of the maxilla and/or palate. Occurs in 1 \nin ~1,000 births.\n\u2022 Results in abnormal facial appearance, \ndefective speech.\n\u2022 Treatment involves surgery and any therapies \n(e.g., speech) to improve related conditions.\nClinical Correlate\n  Cleft Lip, Cleft Palate..."
    },
    {
      "page": 58,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n  Craniosynostosis, Microcephaly, Hydrocephalus\nSource: Humanitas Charity; Science\nMicrocephaly: caused by \nabnormal development of the \nbrain, rather than premature \nclosure of sutures. Often \nresults in mental deficiency.\nHydrocephalus: caused by \nelevated pressure in \nventricles due to CSF \nbuildup (resulting in \nenlarged brain ventricles). \nOccurs 1 in ~1,000 births.\nCraniosynostosis: deformity in the \ncranium due to premature closure of \nsutures/fontanelles. Type of defec..."
    },
    {
      "page": 66,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlate\n  Treacher Collins Syndrome\nSource:  Marsza\u0142ek-Kruk et al. 2021 \nGenetic disorder that involves faulty \nmigration of NCC in pharyngeal arches \n1 and 2. Occurs in 1 in 50,000 births.\nSymptoms include:\n\u2022 Hearing loss\n\u2022 Downturned eyes\n\u2022 Hypoplasia (underdevelopment) of \nmidface\n\u2022 Micrognathia (small lower jaw)\n\u2022 Cleft palate..."
    }
  ],
  "L105": [
    {
      "page": 8,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Lesion produces weakness / paralysis of \nthe lateral rectus muscle\nUnopposed medial rectus pulls eye \ntowards nose\nClinical Correlate\nAbducens Palsy\ncoronal view of \ncavernous sinus\nAbducens lies most medial in the \ncavernous sinus\noculomotor\ntrochlear\nophthalmic\nabducens\nmaxillary\ninternal carotid artery\nThis placement puts the nerve the \nmost at risk for compression related \nto aneurysms and blood clots\n8..."
    },
    {
      "page": 38,
      "keywords": [
        "clinical correlate"
      ],
      "text": "CN V \u2014 Trigeminal\nClinical Correlates\nTrigeminal neuralgia (tic douloureux)\nMisfiring of one or more branches of \ntrigeminal\nPatients complain of acute, intense pain \non face\nCan be stimulated by a slight breeze\nMost cases are idiopathic\nTreatment varies from local anesthesia to nerve resection\n29..."
    },
    {
      "page": 39,
      "keywords": [
        "clinical correlate"
      ],
      "text": "CN V \u2014 Trigeminal\nClinical Correlates\nTMJ disorders\nProblem related to the temporomandibular jaw joint\nUnbalanced muscle firing produces\nCan lead to tooth grinding (bruxism) \nMisaligned teeth\nJaw tenderness\nHeadaches\nLock jaw\nEar pain (e.g., through auriculotemporal nerve aggravation)\n30..."
    },
    {
      "page": 49,
      "keywords": [
        "clinical correlate"
      ],
      "text": "CN VII \u2014 Facial\nClinical Correlate\nBell\u2019s Palsy\nLesion to one or more branches of parotid plexus\nCauses partial / total paralysis of ipsilateral \nfacial muscles\nMost cases are idiopathic\nSymptoms usually to resolve over weeks / months\nOccasionally Bell\u2019s Palsy is permanent\nSylvester Stallone\n(permanent partial Bell\u2019s Palsy)\n40..."
    },
    {
      "page": 62,
      "keywords": [
        "clinical correlate"
      ],
      "text": "CN X \u2014 Vagus\nClinical Correlates\nRecurrent laryngeal nerve damage\nResult of surgical accidents\ne.g. thyroid tumour removal\nConsequence of compression from tumours or \naneurysms\nLesion produces partial / total paralysis of most \nlaryngeal muscles\nUnilateral lesion result in a voice that sounds hoarse\nBilateral lesion produces muteness and trouble \nbreathing (vocal folds can\u2019t abduct)\nOnly muscle left unaffected is the cricothyroid\n12..."
    },
    {
      "page": 64,
      "keywords": [
        "clinical correlate"
      ],
      "text": "CN XI \u2014 Spinal Accessory\nClinical Correlates\nCN XI can be damaged in whiplash accidents or during birth\nTrapezius weakness / paralysis\nShoulder drop Torticollis\nSternocleidomastoid hypertonicity \nor entrapmentShoulder slopes towards side of \nlesion Head tilts towards lesion. Face turns away\n14..."
    },
    {
      "page": 68,
      "keywords": [
        "clinical correlate"
      ],
      "text": "CN XII \u2014 Hypoglossal\nClinical Correlate\nLesions to hypoglossal present as weakness \nor paralysis of most tongue muscles\nA common test for hypoglossal damage is \nto have patient stick out tongue\nWeakened / paralyzed genioglossus will \npresent asymmetric activation\nResults in the tongue deviating to the \nlesion side\nHypoglossal lesion test (Genioglossus test)\n18..."
    }
  ],
  "L107": [
    {
      "page": 65,
      "keywords": [
        "adverse effect"
      ],
      "text": "27\nTherapeutic index (TI) is an estimate of the safety of a drug.\n\u2022 Median effective dose (ED50): The dose of a drug required to produce a \nspecified effect in 50% of the population.\n\u2022 Median lethal dose (LD50): The dose of a drug that is lethal in 50% of the \npopulation.\n\u2022 Median toxic dose (TD50): The dose of a drug that produces a specified toxic \neffect in 50% of the population.\nThe therapeutic index relates the dose of a drug required to produce a desired \neffect to the dose that produces a..."
    },
    {
      "page": 66,
      "keywords": [
        "adverse effect"
      ],
      "text": "Citation: Chapter 3 Pharmacodynamics: Molecular Mechanisms of Drug Action, Brunton LL, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14e; \n2023, Figure 3-10. Available at: https://accessmedicine.mhmedical.com/content.aspx?bookid=3191&sectionid=269715460 Accessed: June 06, 2023\nCopyright \u00a9 2023 McGraw-Hill Education. All rights reserved\nRelation of the therapeutic window of drug concentrations to therapeutic and adverse \neffects in the population. The ordinate is li..."
    },
    {
      "page": 67,
      "keywords": [
        "adverse effect"
      ],
      "text": "Question: You are invited to pause your computer.\n\u2022 What is the clinical value of the therapeutic index and therapeutic \nwindow?\n\u2022 The therapeutic index relates the dose of a drug required to produce a desired \neffect to the dose that produces an undesired effect. It is an estimate of the \nsafety of a drug.\n\u2022 The therapeutic window is the dosage range of a drug that provides safe and \neffective therapy with minimal adverse effects.\n\uf041 This range does not guarantee safety or efficacy in individual..."
    },
    {
      "page": 71,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Cellular regulation of drug-receptor interactions can alter the response to the agonist over time. \nDiminished responsiveness (tolerance/tachyphylaxis) due to continuous or repeated exposure \nto an agonist results from receptor desensitization and downregulation. After withdrawal of the \nagonist, the cells recover full responsiveness to a subsequent addition of agonist \n(resensitization). \n\u2022 An increased density of membrane receptors \u2013 receptor supersensitivity \u2013 can result from \ncontinuous or..."
    },
    {
      "page": 75,
      "keywords": [
        "adverse effect"
      ],
      "text": "Answer to the Question\n\u2022 What is the clinical value of the therapeutic index and therapeutic \nwindow?\n\u2022 The therapeutic index relates the dose of a drug required to produce a desired \neffect to the dose that produces an undesired effect. It is an estimate of the \nsafety of a drug.\n\u2022 The therapeutic window is the dosage range of a drug that provides safe and \neffective therapy with minimal adverse effects.\n\uf041 This range does not guarantee safety or efficacy in individual patients.\n37..."
    }
  ],
  "L109110": [
    {
      "page": 74,
      "keywords": [
        "clinical correlate",
        "adverse effect"
      ],
      "text": "Selective for a specific conformational structure of a drug\nSaturable (they have a maximum capacity)\nExpression can be induced (increased) or downregulated (decreased)\nSubject to competitive inhibition of co -transported substances\nSubject to noncompetitive inhibition \n(binding of inhibitor to allosteric site, inhibiting translocation process)\nGenetic variants of transport proteins can affect drug response in the individual \npatient\n\uf0de Clinical correlate: \nPotential for ADVERSE EFFECTS and DRUG I..."
    },
    {
      "page": 80,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Routes of Administration\nEnteral\n\u2022 Oral, sublingual, buccal\n\u2022 Enteral tube\n\u2022 Rectal\n\uf0de Clinical correlate: The upper \nsmall intestine is the major site \nof oral drug absorption.\nParenteral:\nCommon routes:\n\u2022 Intravenous (IV)\n\u2022 Intramuscular (IM)\n\u2022 Subcutaneous (subQ)\n\u2022 Intrathecal (IT)\nAlternative routes:\n\u2022 Intradermal\n\u2022 Intra-osseous\n\u2022 Intra-arterial\n\u2022 Intraventricular\nTransdermal / Transmucosal\n\u2022 Drug delivery through the \nskin or mucosa to the \nsystemic circulation\nTopical: Application for loca..."
    },
    {
      "page": 95,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Different routes of administration are used in clinical medicine for various \nreasons, such as convenience, rapid onset of action, maximizing \nconcentration at the site of action, avoiding the first -pass effect, and \nminimizing adverse effects.\n\u2022 The rate and extent of drug distribution are determined by physicochemical \nproperties of the drug, and the physiologic factors of cardiac output, regional \nblood flow, capillary permeability, and tissue volume. Extensive binding to \ninert proteins a..."
    },
    {
      "page": 97,
      "keywords": [
        "adverse effect"
      ],
      "text": "Route\n(Bioavailability)\nAbsorption \nPattern Utility Limitations and Precautions\nOral (enteral)\n(<5-100%)\nVariable\nAffected by on \nmany factors\nSafest, most convenient and economical \nroute of administration\n\u2022 Limited absorption; potentially erratic and \nincomplete\n\u2022 Food may affect absorption\n\u2022 Drugs may be metabolized before reaching \nsystemic circulation\nCYPs (esp. CYP3A4/5) are present in \nintestinal epithelial cells.\n\u2022 GI irritation\n\u2022 Patients self-administer so adherence to \ntherapy is nece..."
    },
    {
      "page": 100,
      "keywords": [
        "adverse effect"
      ],
      "text": "Route\n(Bioavailability) Absorption Pattern Utility Limitations and Precautions\nIntraosseous \ninfusion\nRapid\n(highly vascular \nintramedullary space,\ndrains to the venous \nsystem)\n\u2022 Very rapid onset\n\u2022 Bypass first-pass effect\n\u2022 Useful for administration of most \ndrugs\n\u2022 Large fluid volumes can be \nadministered to injured or \ndehydrated patients\n\u2022 Useful when trial of IV access \nunsuccessful in critically ill patient\n\u2022 Extravasation\n\u2022 Infection\n\u2022 Soft tissue necrosis\n\u2022 Injury to growth plate\n\u2022 Bone..."
    }
  ],
  "L112": [
    {
      "page": 8,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Olfactory\nClinical Correlates\nAnosmia\nSmell \u201cblindness\u201d\nCauses can be\nChemical (damage to epithelium)\nMechanical (damage to cribriform plate)\nAffects taste and appetite\nInability to detect spoiled food and dangerous situations (e.g., gas leaks)\nCongenital (failure of proper CN I development)\nViral \u2014 originally a CoViD-19 symptom\nAnosmia affects quality of life\n8..."
    },
    {
      "page": 17,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Taste\nClinical Correlate\nAgeusia\nTaste loss\nToxic chemical exposure\nHead trauma\nCaused by:\nCan lead to inadvertent food poisoning\nLargely affects quality of life\nCan also lead to poor nutrition\nOften coupled (and confused) with \nanosmia\nViral \u2014 originally a CoViD-19 symptom\nadding more sugar and salt to foods in an attempt to regain taste\n17..."
    },
    {
      "page": 40,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Vision: The Eye\nClinical Correlates\nPresbyopia\nLens loses elasticity with age\nStretched lens has trouble \u201cbouncing \nback\u201d to its original shape\nNear-point focusing ability is reduced\nTreatment includes corrective lenses \nor multifocal / presbyLASIK\n21..."
    },
    {
      "page": 41,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Vision: The Eye\nClinical Correlates\nCataract in 55-year old male\nHealthy lens next to two lenses \nwith various degrees of cataracts\nCataracts\nProtein breakdown exceeds repair rate \nas we age\nDenatured proteins build up in the lens \nthickening and clouding it\nHypertension, poor nutrition & smoking \nmay increase rates of cataract formation\n68% of U.S. pop over 80, have / had cataracts\nRequires surgical intervention\nPartial / total lens replacement\nDown and Turner\u2019s syndrome may \nincrease chance of..."
    },
    {
      "page": 42,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlates\nGlaucoma\nAqueous humour is continuously produced \nby the ciliary body\nThe humour is continuously drained \nthrough the scleral venous sinus \n(canal of Schlemm)\ncanal of Schlemm\nless serious\nmore serious\nLeft untreated, glaucoma will cause blindness \ndue to optic nerve compression\nBlockage of this flow causes stagnation \nand cloudiness\nVision: The Eye 23..."
    },
    {
      "page": 43,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical Correlates\nRetinal detachment\nNeural layer of retina requires ocular \npressure to maintain attachment to choroid\nInjuries that reduce intraocular pressure \nput the retina at risk of detachment\nPatients complain of flashes and specs \nof light\nRetinal detachments are immediate \nmedical emergencies\nVision: The Eye 24..."
    },
    {
      "page": 60,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Hearing\nClinical Correlates\nHearing Loss\nCan be congenital or acquired\nConductive hearing loss\nAffects the middle ear\nResult of damage to:\nPeople speak softly thinking they are loud\nCan be treated surgically or with a hearing aid\nTympanum \u2014 perforation / tear\nEar ossicles \u2014 scarring from prolonged \n             inflammation\n16..."
    },
    {
      "page": 61,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Hearing\nClinical Correlates\nHearing Loss\nSensorineural hearing loss\nAffects the inner ear\nResult of damage to:\nstereocilia (\u201chair\u201d cells)\ncochlear nerve or associated brain relays\nCochlear implants used, but reclaimed sound is still crude\nCan be congenital or acquired\n17..."
    },
    {
      "page": 62,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Hearing\nClinical Correlates\nTinnitus\nAffects 15\u201320 % of U.S. population\nAge-related loss of \u201chair\u201d cells along cochlea\nLoss is often at higher frequencies\nRinging sensation whenever brain \u201cchecks\u201d \nthose frequencies\nexcessive noise (construction sites, concerts)\nside-effect of some drugs\nRinging is constant and often without a stimulus\nSymptom of some other causes such as:\n18..."
    },
    {
      "page": 63,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Hearing\nClinical Correlates\nSensorineural hearing loss has increased 30% in the past 20 years\nA screenshot of a cell phone\nDescription automatically generated\nEar buds are likely to blame as they don\u2019t form a tight seal around the ear\nSound leakage is countered by increasing volume to deceptively \ndangerous levels\nhttps://osteopathic.org/what-is-osteopathic-medicine/headphones-hearing-loss/\n19..."
    },
    {
      "page": 64,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Hearing\nClinical Correlates\nBenign Paroxysmal Position Vertigo (BPPV)\nBPPV has multiple causes\nblunt trauma to head\nage-related weakening of tissue \nidiopathic (most common)\nOccurs when otoliths break free from utricle\nFree-floating otoliths enter SCC producing \nconflicting signals to the brain about head \norientation\n20..."
    },
    {
      "page": 65,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Hearing\nClinical Correlates\nBenign Paroxysmal Position Vertigo (BPPV)\nPatients experience intense, debilitating vertigo\nBPPV usually resolves on its own via otolith \nresorption\nCanalith repositioning (Epley Maneuver)\nSurgery\nVertigo lasts anywhere from minutes to months\nEpley maneuver\n21..."
    },
    {
      "page": 68,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Coupled Senses\nClinical Correlate\nNystagmus\nResult of a delay in the vestibulo-ocular reflex\nAcquired nystagmus\nCongenital nystagmus\nresults in resting nystagmus\nalcohol\ndrug use (opiates, barbiturates, marijuana)\nheritable trait (recessive) Michael T eixido MD \nhttps://www.youtube.com/watch?v=zeuYnPUv5YU\n24\nOften benign, but rare debilitating cases can be \ntreated pharmacologically\n..."
    }
  ],
  "L115": [
    {
      "page": 6,
      "keywords": [
        "adverse effect"
      ],
      "text": "Citation: Chapter 3 Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action, Katzung BG, Vanderah TW. Basic & Clinical Pharmacology, 15e; \n2021, Figure 3-1. Available at: https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectionid=250594300 Accessed: August 17, 2021\nCopyright \u00a9 2021 McGraw-Hill Education. All rights reserved\nThe relationship between dose and effect can be separated into pharmacokinetic (dose-concentration) and pharmacodynamic \n(concentra..."
    },
    {
      "page": 57,
      "keywords": [
        "clinical correlate"
      ],
      "text": "If dosing rate exceeds elimination capacity, steady state cannot be \nachieved \u2026the concentration will keep rising as long as dosing \ncontinues.\nChanging the dosing rate for a drug with nonlinear kinetics is \ndifficult and unpredictable. \nThree drugs exhibit zero-order kinetics at therapeutic concentrations: \nEthanol, aspirin (anti-inflammatory doses), and phenytoin.\nMost drug elimination pathways will become saturated if the dose \nis high enough\u2192\u2026\u2192 toxicity.\nSaturable elimination: Clinical corre..."
    }
  ],
  "L126": [
    {
      "page": 2,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. Identify the sulfonamides\u2019 clinically relevant class and drug -specific \npharmacokinetics properties .\n2. Differentiate the mechanisms of action, resistance, and cross -resistance for the \nsulfonamides and trimethoprim.\n3. Give examples of the therapeutic applications of each of the clinically used \nsulfonamides, trimethoprim, and trimethoprim -sulfamethoxazole (TMP-SMX) in \nrelation to their specific spectrums of activity.\n4. Explain the mechanisms of potential adverse reactions and drug int..."
    },
    {
      "page": 6,
      "keywords": [
        "adverse effect"
      ],
      "text": "Key points\nSulfonamides\nSulfonamides are not used alone for the treatment of systemic infections due to resistance.\nTherapeutic uses: Trimethoprim and sulfamethoxazole ( TMP-SMX) fixed-combination for a variety of \ninfections; malaria (sulfadoxine and pyrimethamine); toxoplasmosis (sulfadiazine and pyrimethamine); \nulcerative colitis and rheumatoid arthritis (sulfasalazine); \nTopical: antibacterial ophthalmic drops (sulfacetamide), burn creams/powder (silver sulfadiazine, mafenide \nacetate)\nToxi..."
    },
    {
      "page": 7,
      "keywords": [
        "adverse effect"
      ],
      "text": "Key points\nTrimethoprim: Weak base structurally similar to folic acid\nPK: Good tissue penetration, hepatic metabolism (CYP2C9), high concentrations of intact drug excreted in \nurine; t\u00bd adults 8-12 hours (about the same as sulfamethoxazole that is combined with)\nAction: Dihydrofolate reductase (DHFR) inhibitor that blocks the conversion of dihydrofolate to active \ntetrahydrofolate, the second step in bacterial folate synthesis.\nAntibacterial effect: Bacteriostatic\nSelective toxicity: Much greate..."
    },
    {
      "page": 16,
      "keywords": [
        "adverse effect"
      ],
      "text": "Sulfonamides: Adverse Effects\nSulfonamide Hypersensitivity Reactions\n(cross-reactivity among sulfonamides)\nFever and\nSkin reactions\nExfoliative \ndermatitis\nPhotosensitivity\nSJS / TEN\nHepatitis\n Hematopoietic \ndisturbances\n\uf041 Serious adverse effects occur \nrarely but are potentially fatal and \ninclude dermatologic reactions, \nhepatic necrosis, aplastic anemia, \ngranulocytopenia, thrombocytopenia. \nDiscontinue the drug at first signs \nof rash or serious adverse \nreaction.\ngranulocytopenia\nthrombocy..."
    },
    {
      "page": 24,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. What is the bacterial enzyme that sulfonamides target?\n2. What is the antibacterial spectrum of sulfonamides?\n3. What are resistance mechanisms?\n4. What organisms are intrinsically resistant to folate synthesis inhibitors?\n5. Why are sulfonamides combined with a DHFR inhibitor for treatment of systemic infections?\n6. What are the names of the sulfonamide and the DHFR inhibitor in fixed-combination for \ntreatment of bacterial infections?\n7. What are the names of the sulfonamides and the DHFR i..."
    },
    {
      "page": 34,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. Identify the fluoroquinolones\u2019 (FQs) clinically relevant class and drug -specific \npharmacokinetics properties.\n2. Differentiate the mechanisms of action, resistance, and cross -resistance for \nthe fluoroquinolones.\n3. Give examples of the therapeutic applications of each of the clinically used \nfluoroquinolones in relation to their specific spectrums of activity.\n4. Explain the mechanisms of potential adverse reactions and drug interactions \nfor the fluoroquinolones.\n5. Correlate the common ..."
    },
    {
      "page": 39,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 FQs class pharmacokinetic properties: oral and parenteral administration, large volumes of distribution, \nlow to moderate plasma protein binding, minor hepatic metabolism, high bioavailability, mainly renal \nexcretion, drug-specific half-lives. \n\u2022 Parameters associated with efficacy (PK -PD profile): concentration-dependent effects and AUC24/MIC \nratio with organism-specific post-antibiotic effect. Cmax/MIC and AUC24/MIC goals are listed in the drug \nmonographs.\n\u2022 Nausea, vomiting, and diarrhe..."
    },
    {
      "page": 42,
      "keywords": [
        "adverse effect"
      ],
      "text": "A treatment is clinically relevant if it provides a positive benefit in how the patient feels, functions, \nand/or survives \u2013 the perception of benefit by the patient \u2013 and outweighs potential harm = \noptimization of therapy.\nKnowing the pharmacokinetic properties enables prescribing the right drug for the individual patient \nat the right dose by the right route of administration and the right duration for optimal efficacy \n(benefit to the patient) and minimal harm.\nADME: \n\u2022 correct route of admi..."
    },
    {
      "page": 48,
      "keywords": [
        "adverse effect"
      ],
      "text": "US Boxed Warnings\n\u2022 CNS: \nSeizures (rare), \u2191intracranial pressure, \nheadache, dizziness, insomnia, \nnightmares, depression, psychosis\n\u2022 Peripheral neuropathy \n(can be irreversible)\n\u2022 Tendon rupture\n\u2022 Myasthenia gravis exacerbation\nAdditional potential AEs\n\u2022 Nausea/vomiting/diarrhea\n\u2022 QT interval prolongation\n\u2022 Glucose dysregulation (serious \nhypoglycemia/hyperglycemia in \ndiabetic patients)\n\u2022 Aneurysm / aortic dissection\n\u2022 C. difficile or Candida infection\n\u2022 Phototoxicity\n\u2022 Hypersensitivity reac..."
    },
    {
      "page": 49,
      "keywords": [
        "adverse effect"
      ],
      "text": "Pregnancy\n\u2022 FQs Cross the placenta and can be \nfound in cord blood\n\u2022 No specific teratogenic effect or \nincreased pregnancy risk has been \nidentified.\n\u2022 May be used in the treatment of \nmultidrug resistant tuberculosis, \ninhalational anthrax, and plague (Yersinia \npestis) during pregnancy.\nPediatrics\n\u2022 Dosing recommendations are \navailable for infants \uf0b36 months old and \nchildren \n\u27a2FQs are not first-line agents in pediatric \npatients. A FQ may be considered after \nassessment of risks and benefits..."
    },
    {
      "page": 51,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. How is gaining knowledge about class and drug-specific PK properties relevant to optimizing \ndrug therapy for the individual patient?\n2. What parameters are associated with clinical efficacy (and provide dosing guidance)?\n3. What are the bacterial targets of the FQs?\n4. What are the chromosomal and plasmid-mediated resistance mechanisms? \n5. Which mechanisms confer low-level resistance ?\n6. What risks must be weighed against the benefit when considering therapy with a FQ?\nCheck your knowledge..."
    },
    {
      "page": 55,
      "keywords": [
        "adverse effect"
      ],
      "text": "Toxicities: FDA safety alerts: \nCNS effects, peripheral neuropathy, tendinitis/tendon rupture, worsening of myasthenia \ngravis muscle weakness, QTc interval prolongation, hypersensitivity reactions.\nPregnancy: MDR tuberculosis, inhalation anthrax and serious infection if benefit \noutweighs risk\nPediatrics: Infants \uf0b36 months old and children if benefit outweighs risk\nOlder patient: Adverse effects may be increased in the elderly.\nDrug interactions: \nCiprofloxacin: CYP1A2 (theophylline toxicity ri..."
    },
    {
      "page": 56,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. How is gaining knowledge about class and drug-specific PK properties relevant to optimizing drug therapy for the \nindividual patient?\n2. What parameters are associated with clinical efficacy (and provide dosing guidance)?\n3. What are the bacterial targets of the FQs?\n4. What are the chromosomal and plasmid-mediated resistance mechanisms? \n5. Which mechanisms confer low-level resistance ?\n6. What risks must be weighed against the benefit when considering therapy with a FQ?\nCheck your knowledge..."
    }
  ],
  "L133": [
    {
      "page": 4,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Cells of the Central Nervous System:  NEURONS\nNissl stain\nCh.5, Essential Neuroscience 2nd ed. Wolters Kluwer/Lippincott Williams\n- characterized by the presence of soma (intracellular organelles), branching dendrites \n(often w/ spines), axon initial segment, branching axon, and axon terminals (synapses)\n- electrically excitable cells that can release and respond to neurotransmitters via \nneuronal connections/synapses\n- almost all neurons produced before birth and almost entirely non-renewable.\n..."
    },
    {
      "page": 6,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Office of Academic Affairs \nC\n6\n- spines found on the dendrites of many neurons such as neocortical neurons, Purkinje neurons, etc.\n- synapses are preferentially made on spines\nHuman neocortical neuron (Benavides-Piccione et al. Cerebral \nCortex 2013)\nParts of NEURONS: Dendrites & dendritic spines\n\u2022Estomih Mtui MD, Gregory Gruener MD, \nMBA and Peter Dockery BSc, PhD Fitzgerald's \nClinical Neuroanatomy and Neuroscience, 6, 63-74\nClinical correlate:\nDendritic spines are decreased in \nneocortical n..."
    },
    {
      "page": 7,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Parts of a NEURON: Axon, branches,  terminals \n- axons found on nearly all neurons \n- axons can vary widely in length, shape, and number of \nbranches (emanating from axon initial segment/hillock).\n- axon terminals make \u201ccontact\u201d with other neurons or \nmuscle and form synapses\n- communicating \u201cwires\u201d of neurons that do the \u201ctalking\u201d\nCh.5, Essential Neuroscience 2nd ed. Wolters Kluwer/Lippincott Williams\n7\nAxon initial segment (hillock) \u2013 area with large \nnumbers of ion channels to initiate the ac..."
    },
    {
      "page": 8,
      "keywords": [
        "clinical correlate"
      ],
      "text": "M. Rasband Baylor University, http://videocast.nih.gov/summary.asp?Live=17068&bhcp=1\nAxons:  Nodes of Ranvier\nrepeating segments of localized density of Na+/K+ channels \nand other proteins used to regenerate action potentials and \nincrease conduction speed and fidelity down the length of the \naxon. Found in-between segments of myelin.\nClinical correlate:\nCNTNAP2 gene encodes for a protein that is highly localized at \nthe nodes of Ranvier and involved in clustering of K+ channels \nat the node. Ge..."
    },
    {
      "page": 9,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Axon terminal (terminal bouton) forms the chemical \nsynapse!\n- site where neurons functionally communicate with one \nanother via neurotransmitter release.\n- Most common type of synapse\n- Slower form of neural communication but still pretty fast ~1-5ms\nAxon\nDendrite\nPresynaptic neuron \u2013 sending info/message\nPostsynaptic neuron \u2013 receiving message\nClinical correlates \u2013 so many!\n-neuro/psych disorders\n-drugs of abuse/addiction\n-sleep/wake, hunger/satiety\n-SHANK3 mutations & autism\n..."
    },
    {
      "page": 12,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Electrical synapses:\n Gap junctions/Connexons\n12\nNeurons are \u201cconnected\u201d to one another at the synapse\n- the site where neurons functionally communicate with one another\nGap junctions allow direct ion & small \nmolecule flow from one neuron to the \nother. Usually bidirectional.\nClinical correlate:\nCertain connexins expressed in specific cell types. \n~30 disease due to connexin gene mutations. \u2022E Mtui MD, G Gruener MD, MBA and P Dockery BSc, PhD  Fitzgerald's \nClinical Neuroanatomy and Neuroscienc..."
    },
    {
      "page": 14,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Neuronal Cilia \n- every neuron has a cilium (~2-4um long) which generally emerges from the cell body\n-  function of the cilium is poorly understood\nSarkisian & Guadiana 2014\n14\nClinical correlate: serious neurodevelopmental disorders are associated with mutation of \nGenes important for cilia development. \nARL13B gene mutation causes defecitis in cilia development and Joubert Syndrome \u2013 characterized by \nmidbrain & hindbrain malformations, intellectual disability, retinal dystrophy, cystic renal ..."
    },
    {
      "page": 19,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Gap junctions & Electrical synapses in Astrocytes\n19\n- Connected to other astrocytes as well as oligodendrocytes by gap junctions  \n- Can respond/\u201dreact\u201d to tissue damage and form a glial scar but role not well \nunderstood  (i.e. harmful or helpful such as in spinal cord injury)\nClinical correlate:\nGlial fibrillary acid protein (Gfap) is the gold standard molecular marker for reactive astrocytes and is used for detection \nof astro-gliosis (brain injury) and tumors made up of astroctyes (i.e. ast..."
    },
    {
      "page": 24,
      "keywords": [
        "clinical correlate"
      ],
      "text": "Clinical correlates\nAutoimmune disorder where patients have IgG against MOG - \nmyelin oligodendrocyte glycoprotein. MOG is a glycoprotein \nuniquely expressed in oligodendrocytes in the CNS.  MOG \nantibody disorder (MOGAD) is an idiopathic, inflammatory, \ndemyelinating disease of the central nervous system (CNS). \nDiverse peripheral and central symptoms including optic neuritis \n(loss or blurry vision, eye pain), transverse myelitis (weakness, \nnumbness, pain, loss of bowel or bladder control).\n ..."
    }
  ],
  "L117": [
    {
      "page": 7,
      "keywords": [
        "adverse effect"
      ],
      "text": "What you need to know and understand: Terminology (the language of medicine)\nThe definitions and explanations are in the Notes Handout.\nToxicokinetics DNA toxicity Pregnancy and Lactation Labeling Rule \nToxicodynamics Mutagenesis Fetotoxicity\nAdverse drug reactions Carcinogenesis Teratogenesis\nAdverse drug events Hepatotoxicity Neonatal abstinence syndrome\nPolypharmacy Nephrotoxicity Pharmacogenomics\nPrescribing cascade Pulmonary toxicity Pharmacogenetics\nOn-target adverse effects Cardiotoxicity..."
    },
    {
      "page": 13,
      "keywords": [
        "adverse effect"
      ],
      "text": "Copyright \u00a9 Wolters Kluwer\nFrom: 6 Drug Toxicity\nOn-target and off-target adverse drug effects.\nPrinciples of Pharmacology: The Pathophysiologic Basis of Drug Therapy Fourth Edition, 4e,  2017\nADRs are typically,\n\u2022 Predictable: Based on knowledge of the mechanisms of \naction and adverse effects, distribution to tissues, and \ndose-response relationship\n\u2022 Dose-dependent: Related to the concentration of drug in \nthe body and to the duration of the exposure\nOFF-TARGET effect results from the drug in..."
    },
    {
      "page": 14,
      "keywords": [
        "adverse effect"
      ],
      "text": "Cellular toxicity\n\u2022 Apoptosis\n\u2022 Necrosis\nDNA damage\n\u2022 Mutagenesis:\nGene mutations give rise to \naltered proteins.\n\u2022 Carcinogenesis\nMutations in genes that \nregulate cell growth may lead \nto induction of cancer.\nOrgan toxicity\n\u2022 Liver\n\u2212 Hepatitis / necrosis\n\u2212 Cirrhosis\n\u2022 Kidney\n\u2212 Glomerular nephropathy \n\u2212 Tubular necrosis\n\u2212 Interstitial nephritis\n\u2022 Nerves\n\u2212 Neuropathy\n\u2212 Seizures\n\u2212 Coma\n\u2022 Bone marrow toxicity\n\u2212 Neutropenia\n\u2212 Anemia\n\u2212 Thrombocytopenia\nToxic effects may be acute, delayed, or cumulat..."
    },
    {
      "page": 18,
      "keywords": [
        "adverse effect"
      ],
      "text": "Recall questions. Please pause the video and try to answer them \nwithout looking back at the slides.\n\u2022 What are the causes of the common and predictable adverse effects?\n\u2022 What is the meaning of on-target and off-target effects?\n\u2022 What cellular and organ damage can occur as a result of drug -induced \nadverse effects?\n\u2022 Look back at the slides for the answers...."
    },
    {
      "page": 19,
      "keywords": [
        "adverse effect"
      ],
      "text": "Therapeutic Drug Use During Pregnancy\nThe therapeutic benefit of medication use in the expectant mother must be \nweighed against the potential adverse effects on fetal growth and \ndevelopment. \nHealth risks and benefits of drug therapy to both the mother and the fetus \nmust be considered. \nThe vast majority of drugs are not recommended during pregnancy.\nAll prescribers have the responsibility of educating pregnant patients not to \ntake any medications, prescription, over -the-counter, or recreat..."
    },
    {
      "page": 20,
      "keywords": [
        "adverse effect"
      ],
      "text": "Three subsections:\n1. Pregnancy including labor and delivery: \n\u2022 Pregnancy registry collects data and notes any potential risk of medication use on the developing \nfetus and the mother.\n\u2022 Risk summary provides information on potential adverse effects on developing fetus throughout \npregnancy and PK parameters altered during pregnancy.\n\u2022 Clinical considerations are provided about initiation, continuation, and withdrawal of treatment \nduring pregnancy and the data are listed in the drug monographs..."
    },
    {
      "page": 22,
      "keywords": [
        "adverse effect"
      ],
      "text": "Harmful effects of drugs taken by the mother during pregnancy\non the fetus and the neonate \nFetal effects\nFetotoxicity Injury to the fetus from a substance that enters the maternal and \nplacental circulation, which may cause fetal malformations, altered \ngrowth, or in utero death\nTeratogenicity The induction of defects of the fetus; exposure must occur during \na critical developmental period\nTeratogen Any agent that acts during embryonic or fetal development to produce a \npermanent alteration of..."
    },
    {
      "page": 23,
      "keywords": [
        "adverse effect"
      ],
      "text": "Neonatal abstinence syndrome: A drug-withdrawal syndrome that follows in utero \nexposure to maternal opioids, alcohol, benzodiazepines, barbiturates, others\n23\nOther adverse effects of \ndrug on the newborn \ninclude: \npremature birth, \nlow birth weight, \nand the teratogenic or \notherwise fetotoxic effects \nof specific drugs such as \nheart defects, pulmonary \nhypoplasia, cerebral \ncomplications and other \nbirth defects...."
    }
  ],
  "L118": [
    {
      "page": 3,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. Classify the drug-drug interactions resulting in additive, synergistic, or \nantagonistic effects.\n2. Describe the receptor-mediated and non-receptor-mediated \npharmacodynamic mechanisms of drug -drug interactions and their effects.\n3. Explain the pharmacokinetic mechanisms of drug -drug interactions related to \nabsorption, metabolism, distribution, and excretion and their effects.\n4. List the common inducers and inhibitors of CYP3A4 and P -glycoprotein, and \nthe effect of smoking use on the C..."
    },
    {
      "page": 7,
      "keywords": [
        "adverse effect"
      ],
      "text": "Key points\n\u2022 Mechanisms of drug-disease interactions: Drugs can exacerbate diseases. \n\u2022 Knowledge of drug-drug, drug-food, drug-herbals (botanicals), and \ndrug-disease interactions, careful selection of therapeutic alternatives, \nand continuous monitoring to identify adverse effects could reduce the \nrisks of adverse drug events.\n\u2022 Be able to explain the mechanisms and potential adverse effects of drug \ninteractions when given examples.\nNYITCOM\u2019s Medical Library includes access to\nUpToDate / Lex..."
    },
    {
      "page": 11,
      "keywords": [
        "adverse effect"
      ],
      "text": "Examples of PD DDIs by Antagonistic Mechanisms\n11\nCompetitive antagonism: One drug competes with another drug for the active site\nmorphine (MOR agonist) + naloxone (MOR antagonist) \u2192 treatment of opioid overdose\n\u2022 Both drugs bind the active site of mu opioid receptor (MOR). Naloxone blocks the receptor and \nprevents the opioid from activating the receptor \u2192 may cause abrupt withdrawal symptoms\nnerve agent (poison) + atropine (anticholinergic) \u2192 treatment of cholinergic poisoning\n\u2022 The nerve agen..."
    },
    {
      "page": 12,
      "keywords": [
        "adverse effect"
      ],
      "text": "Pharmacokinetic Drug Interactions \nModification of ADME properties may affect levels of one or both interacting drugs \nAlterations Mechanism Possible Effect\nAbsorption Sequestration of drug in gut or increased gastric pH \nreduces systemic levels\nReduces therapeutic effect\nDistribution Changes in volume of distribution\n\uf0ador\uf0af fluid or tissue mass may \uf0ador\uf0af the plasma \nconcentration of free drug\nIncrease risk of adverse effects or reduce \ntherapeutic effect, respectively\nInhibiting efflux transporter..."
    },
    {
      "page": 21,
      "keywords": [
        "adverse effect"
      ],
      "text": "4. A patient with several comorbidities treated with various drugs is evaluated for an oral antiviral drug \nthat contains a potent CYP3A4 inhibitor for the treatment of COVID-19. What effects may be \nanticipated when the antiviral is taken together with the patient\u2019s chronic medications?\n\u2022 PK metabolism: Inhibiting the metabolism of the concurrent drugs that are CYP3A4 substrates \ncan lead to elevated blood levels of the substrate drugs and increase the risk of adverse effects. \n5. What can the ..."
    },
    {
      "page": 27,
      "keywords": [
        "adverse effect"
      ],
      "text": "4. A patient with several comorbidities treated with various drugs is evaluated for an oral antiviral drug \nthat contains a potent CYP3A4 inhibitor for the treatment of COVID-19. What effects may be \nanticipated when the antiviral is taken together with the patient\u2019s chronic medications?\n\u2022 PK metabolism: Inhibiting the metabolism of the concurrent drugs that are CYP3A4 substrates \ncan lead to elevated blood levels of the substrate drugs and increase the risk of adverse effects. \n5. What can the ..."
    }
  ],
  "L119": [
    {
      "page": 11,
      "keywords": [
        "clinical correlate",
        "adverse effect"
      ],
      "text": "\u2022 Narrow-spectrum \nantimicrobials: \nDrugs effective against a limited \ngroup of microorganisms\n\u2022 Broad-spectrum \nantimicrobials:\nDrugs effective against a wide \nvariety of microbial species\nClinical correlate: \n\u2022 Use the most selective \n(active) drug \n\u2022 that produces the fewest \nadverse effects.\nSpectrum of Activity / Selectivity\n11..."
    }
  ],
  "L120": [
    {
      "page": 3,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. Identify the interrelationship between bacteriology and the pharmacology of antibiotics.\n2. Illustrate the microbial characteristics of gram -positive, gram-negative, aerobic, and \nanaerobic bacteria that are relevant to antibiotic mechanisms and therapy.\n3. Apply the structure-activity relationship of the beta-lactam antibiotics, \nvancomycin, and daptomycin to their mechanisms of action, antibacterial \nspectrums, and mechanisms of resistance.\n4. Describe the class and drug-specific pharmacok..."
    },
    {
      "page": 11,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Classification of gram-negative bacterial beta-lactamases: Ambler Class A, B, C, and D categorize \nthe main resistance patterns.\n\u2022 The mechanisms and effects of the beta-lactamase inhibitors when partnered with a beta-lactam \nantibiotic\n\u2022 The properties of each of the beta-lactam subclasses: \nThe penicillins group: natural, penicillinase-resistant, aminopenicillins, antipseudomonal\nThe cephalosporins group: first-, second-, third-, fourth-, and advanced-generation drugs \nThe carbapenems\nThe mo..."
    },
    {
      "page": 14,
      "keywords": [
        "adverse effect"
      ],
      "text": "Normal human microbiota\n14\nGastrointestinal tract \u2013 mainly colon: The highest microbial density of any human-associated microbial community.\nThe species are far to numerous to list here. Please know those bolded in red, which are related to this lecture.\nIn the normal adult colon, 96\u201399% of the resident bacterial flora consists of anaerobes: \nAnaerobes: Bacteroides species, especially Bacteroides fragilis; Fusobacterium species; anaerobic lactobacilli, eg, \nbifidobacteria; Clostridium spp; anaer..."
    },
    {
      "page": 29,
      "keywords": [
        "adverse effect"
      ],
      "text": "HYPERSENSITIVITY REACTIONS\nEstimated cross-reactivity in patients who reported PCN allergy (without confirmatory testing) range between 0.8% \nand 8.1%, based on retrospective studies.\nUp to 10% of patients report a penicillin allergy. More than 90% do not have an IgE-mediated sensitivity when skin \ntesting is performed. Among those with positive skin testing, 97% will tolerate cephalosporins and 99% will tolerate \ncarbapenems, according to available studies.\nCaution: Remember \u2013 Beta-lactams are ..."
    },
    {
      "page": 37,
      "keywords": [
        "adverse effect"
      ],
      "text": "Check your knowledge\n1. What are the mechanisms of resistance to the beta-lactam antibiotics?\n2. What is the most important adverse effect of the beta-lactam antibiotics as a class?\n3. What are two common secondary infections that can occur with antibiotic use?\n4. Probenecid is an OAT inhibitor that is sometimes used with penicillin for its beneficial drug-\ndrug interaction? What is it?\n5. What is the reason for the recommendation to people taking hormonal contraceptives to \nprevent pregnancy fo..."
    },
    {
      "page": 41,
      "keywords": [
        "adverse effect"
      ],
      "text": "Wong D, van Duin D. Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. Drugs (2017), 77, 615-618; \nPMCID5473160; PMID28303449; doi: 10.1007/s40265-017-0725-1\nMechanisms: Beta-Lactamase Inhibitors\nThe antibacterial spectrum is determined by the beta -lactam antibiotic, \nnot the beta-lactamase inhibitor.\nBeta-lactamase inhibitors have only weak antibacterial activity on their own. \nAdverse effects: hypersensitivity reactions; secondary C. difficile infection\nIrreversible (suici..."
    },
    {
      "page": 50,
      "keywords": [
        "adverse effect"
      ],
      "text": "Natural Penicillins: Adverse Effects\n50\nHypersensitivity reactions, anaphylaxis\nSeizures High dose penicillin\nElectrolyte \ndisturbances\nDrugs are formulated as Na+ and K+ salts.\nPenicillin G aqueous has a short t\u00bd and T>MIC with minimal \npersistent effects.\nI.V. administration 6 times daily or by continuous infusion.\nJarisch-\nHerxheimer \nreaction\nSyphilis: Acute, self-limited, febrile reaction to antibiotic treatment, \nwhich often resolves 12-24 hours without intervention.\nProposed mechanism: Im..."
    },
    {
      "page": 53,
      "keywords": [
        "adverse effect"
      ],
      "text": "Penicillinase-resistant penicillins\n53\nPK Nafcillin, Oxacillin: IM, IV; Dicloxacillin, Cloxacillin: oral\nHepatic elimination (nonrenal clearance)\nDose adjustment not necessary for renal impairment\n\u2022 Caution in patients with hepatic impairment\nActivity MSSA / MSSE: Penicillinase-producing S. aureus, S. epidermidis\nResistance \n(common)\nMRSA / MRSE: Modification of staphylococcal PBPs\nPBP2a (MecA gene) \u2192 very low affinity for all beta-lactam antibiotics\nTherapeutic use MSSA / MSSE infections only\n(..."
    },
    {
      "page": 57,
      "keywords": [
        "adverse effect"
      ],
      "text": "Non-allergic rash: \nMaculopapular rash on trunk and may spread \nto face; usually appears 5-7 days from the \nstart of therapy; may occur earlier or as late as \nday 16\nIncidence is higher in patients with:\n\u2022 Viral infection such as Roseola or \nmononucleosis\n\u2022 Allopurinol + ampicillin or amoxicillin\n\uf042 Differentiate allergic reaction: \nOnset of pruritic urticarial rash within hours of \nfirst dose, cough, fever, and wheezing / \ndifficulty breathing.\nAminopenicillins\nA true allergic reaction is a cont..."
    },
    {
      "page": 60,
      "keywords": [
        "adverse effect"
      ],
      "text": "Piperacillin-Tazobactam\nThe broadest antibacterial spectrum of the penicillins class\n60\nActivity The same activity as the aminopenicillins plus\nPseudomonas aeruginosa\n\u2022 Polar side chains allow the drug to pass through the porins \nof P. aeruginosa and many GNBs (gram-negative bacilli).\nTherapeutic uses Bacteremia, pneumonias, burns, appendicitis, gynecologic \ninfections, urinary tract infections\nAdverse effects\nCongestive heart failure exacerbation: Na + salts, frequent administration\nAbnormal pl..."
    },
    {
      "page": 61,
      "keywords": [
        "adverse effect"
      ],
      "text": "Questions: You may want to pause the video to think about the answers.\n1. Which drug in the penicillins class has the broadest spectrum of activity?\n2. Activity against what microbe sets it apart from the other penicillins?\n3. Which drug in the penicillins class has an extended spectrum of activity and 100% oral \nbioavailability?\n4. Which drug in the penicillins class has excellent activity against, and is preferred, for \nthe treatment of Treponema pallidum infection?\n5. Which gram-negative cocc..."
    }
  ],
  "L123": [
    {
      "page": 3,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. Identify the interrelationship between bacteriology and the pharmacology of antibiotics.\n2. Illustrate the microbial characteristics of gram -positive, gram-negative, aerobic, and \nanaerobic bacteria that are relevant to antibiotic mechanisms and therapy.\n3. Apply the structure-activity relationship of the beta-lactam antibiotics, \nvancomycin, and daptomycin to their mechanisms of action, antibacterial \nspectrums, and mechanisms of resistance.\n4. Describe the class and drug-specific pharmacok..."
    },
    {
      "page": 20,
      "keywords": [
        "adverse effect"
      ],
      "text": "20\nIn addition to class effects\u2026\nInjection reactions: I.M. painful injection; I.V. thrombophlebitis\nRare but serious: Renal tubular necrosis; Interstitial nephritis\nCeftriaxone \n\u2022 Biliary stasis / cholestatic hepatitis\nNeonates: \n\u2022 Hyperbilirubinemia \u2192 kernicterus\n\u2022 Precipitation of Ca2+-containing solutions \u2192 \nlung and kidney damage in neonates\nCefotetan (cephamycin) (Board-relevant)\n\u2022 Hypoprothrombinemia\nVitamin K administration prevents this AE\n\u2022 Disulfiram-like reaction with alcohol \nconsump..."
    },
    {
      "page": 25,
      "keywords": [
        "adverse effect"
      ],
      "text": "Empiric treatment of serious infections in \nhospitalized patients who have recently \nreceived other beta-lactam antibiotics:\n\u2022 lower respiratory\n\u2022 intra-abdominal\n\u2022 pelvic\n\u2022 skin, soft tissue, bone, joint\ncaused by:\n\u2022 gram-positive bacteria\n\u2022 Enterobacterales\n\u2022 Pseudomonas aeruginosa\n\u2022 anaerobes including B. fragilis\nCarbapenems: Treatments and Adverse Effects\n25\n(except ertapenem)\nIn addition to hypersensitivity reactions and other \nside effects common to the class:\n\u2022 Seizures: greatest risk wi..."
    },
    {
      "page": 34,
      "keywords": [
        "adverse effect"
      ],
      "text": "Adverse Effects\n\u2022 Nephrotoxicity: Acute kidney injury (usually in patients with multiple risk factors)\n\u2022 Non-immune anaphylactoid infusion-related reaction\n\u2022 Hypersensitivity reaction (immunogenic)\n\u2022 Phlebitis at injection site\n\u2022 Neutropenia with prolonged therapy (7 to 12 days)\n\u2022 Ototoxicity (rare): hearing loss, vertigo\nDrug Interactions\nIncreased risk when drugs with the same toxicities are given together: \n\u2022 Nephrotoxicity: Aminoglycosides, loop diuretics, amphotericin B, NSAIDs\nMitigation: ..."
    },
    {
      "page": 45,
      "keywords": [
        "adverse effect"
      ],
      "text": "Summary of \u03b2-lactams Adverse Effects\nCholestatic jaundice Beta-lactams excreted in bile (ceftriaxone)\nInterstitial nephritis\nreported rarely:\nMethicillin (withdrawn from market)\nNafcillin; Oxa-; Dicloxa-; Cloxacillin\nDecreased coagulation Cefotetan  (pts w. hypoprothrombinemia)\nSeizures High-dose, especially Penicillin and Imipenem\nElectrolyte imbalances Drugs formulated as Na+ and K+ salts\nJarisch-Herxheimer reaction Inflammatory response to dying Treponema pallidum \n(syphilis); self-limited\nDi..."
    },
    {
      "page": 46,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Vancomycin is a glycopeptide that binds the D -Ala-D-Ala terminal on the lipid carrier -NAG-NAM-\npentapeptide cell wall precursors, which inhibits the polymerization \u2013 transglycosylation \u2013 of the \nglycopeptide subunits, the penultimate step in bacterial cell wall synthesis.\n\u2022 VanA and vanB gene clusters confer resistance in strains of enterococci (VRE) and staphylococci \n(VRSA) due to expression of enzymes that modify cell wall precursor by substituting a terminal D -lactate \nfor D-alanine \u2192 D..."
    }
  ],
  "L124": [
    {
      "page": 3,
      "keywords": [
        "adverse effect"
      ],
      "text": "1. Correlate the aminoglycosides\u2019 structure and pharmacokinetic properties with \ntherapeutic monitoring of serum aminoglycoside concentrations and renal dosing.\n2. Apply the aminoglycosides\u2019 pharmacokinetic / pharmacodynamic profile to dosing \nstrategies.\n3. Explain the aminoglycosides\u2019 mechanisms of antimicrobial action, antimicrobial \nspectrum, and mechanisms of resistance when selecting an aminoglycoside for \nthe individual patient.\n4. Predict the potential adverse effects, drug interactions,..."
    },
    {
      "page": 7,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Several antibiotics produce antimicrobial effects by targeting bacterial ribosomes and inhibiting bacterial \nprotein synthesis.\n\u2022 Bacterial ribosomes are composed of 30S and 50S ribosomal subunits. They differ structurally from \nmammalian cytoplasmic ribosomes, which are composed of 40S and 60S subunits. However, \nmitochondrial ribosomes are similar to bacterial ribosomes in structure and size.\n\u2022 In general, the antibacterial protein synthesis inhibitors are selective for the bacterial ribosom..."
    },
    {
      "page": 12,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 The aminoglycosides class adverse effects are:\n\u2022 nephrotoxicity,\n\u2022 ototoxicity, and \n\u2022 neuromuscular blockade (high doses). \n\u2022 AGs accumulate in the proximal renal tubular cells leading to renal tubular dysfunction and \nglomerular dysfunction. \n\u2022 Drug accumulation in the perilymph of the inner ear can cause vestibular toxicity with vertigo, \nataxia, and loss of balance, and cochlear toxicity with high-frequency hearing loss. Ototoxicity \nmay be irreversible. \n\u2022 Neuromuscular blockade results f..."
    }
  ],
  "L125": [
    {
      "page": 6,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Several antibiotics produce antimicrobial effects by targeting bacterial ribosomes\nand inhibiting bacterial protein synthesis.\n\u2022 Bacterial ribosomes are composed of 30S and 50S ribosomal subunits. They differ structurally from \nmammalian cytoplasmic ribosomes, which are composed of 40S and 60S subunits. However, \nmitochondrial ribosomes are similar to bacterial ribosomes in structure and size.\n\u2022 In general, the antibacterial protein synthesis inhibitors are selective for the bacterial ribosome..."
    },
    {
      "page": 10,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Most of the tetracyclines\u2019 adverse effects are due to direct toxicity or alteration of the \nmicrobiota. Hypersensitivity reactions (skin rashes, drug fever) are uncommon.\n\u2022 GI discomfort due to direct local irritation \u2013 nausea, vomiting, diarrhea \u2013 are the most common \nadverse effects. Secondary infections, ie, C. difficile infection, due to alteration of the normal GI \nflora. Phototoxicity that can result in severe sunburn in sun-exposed skin. Impaired hepatic \nfunction is seen especially in ..."
    },
    {
      "page": 14,
      "keywords": [
        "adverse effect"
      ],
      "text": "\u2022 Clindamycin is oral and IV, distributes well in body fluids but low concentrations in CSF. It penetrates \nwell into abscesses, bones and joints, and is actively taken up into phagocytic cells. It is converted by \nCYP3A4 to inactive metabolites; it is not a CYP inhibitor or inducer. Small amounts of active drug and \nmetabolites are excreted urine and feces. Dose adjustment for renal insufficient is not necessary. It has \na half-life of ~3 hours (2 to 4 divided doses per 24 hours).\n\u2022 Clindamycin..."
    },
    {
      "page": 28,
      "keywords": [
        "adverse effect"
      ],
      "text": "Tetracyclines / Tigecycline Adverse Effects\nSecondary infections C. difficile; Candida\nModification of microbiota\nGI\nNausea / vomiting / non-C. diff. diarrhea\nKidney\nIncreased blood urea nitrogen (BUN) / Azotemia \n(caution in patients with \uf0af renal function)\nFanconi syndrome with outdated TCN\nBones / Teeth (TCNs chelate calcium)\nDeposit in bones/teeth of fetus, growing children\nTCNs are contraindicated in pregnancy, \nnursing infants, and children <8 years old.\nException: Doxy now recommended \uf0a3 21..."
    },
    {
      "page": 35,
      "keywords": [
        "adverse effect"
      ],
      "text": "EKG: The Atlas of Emergency Medicine > Part 2. Specialty Areas > Chapter 23. ECG Abnormalities > Part 3: Rhythm \nDisturbances > Torsades De Pointes > ECG Findings >\n\u2022 GI: Abdominal cramps, nausea, vomiting, and diarrhea \n\u2212 Erythromycin acts on motilin receptors\uf0bdAzithro, Clarithro better tolerated\n\u2022 Cardiac: QTc prolongation \u2192 ventricular arrhythmias \n\u2212 torsades de pointes (\u201ctwisting of the points\u201d)\n\u2022 Hepatotoxicity: esp. erythromycin estolate \n\u2212 Azithromycin-induced liver injury: Hepatitis; most..."
    },
    {
      "page": 42,
      "keywords": [
        "adverse effect"
      ],
      "text": "Chloramphenicol Properties\nPK IV, succinate salt is rapidly converted by esterases to active chloramphenicol \nprotein binding ~60%\nwidely distributed with good penetration of CSF, ocular tissues, prostate \nglucuronide conjugation, inactive metabolites; urine, t\u00bd ~4 h\nActivity Broad-spectrum, bacteriostatic (P . aeruginosa is intrinsically resistant.)\nResistance Drug inactivation by covalent acetylation by bacterial acetyltransferase\nUses Limited: restricted to life-threatening infections when no..."
    },
    {
      "page": 46,
      "keywords": [
        "adverse effect"
      ],
      "text": "Linezolid is a weak \nmonoamine oxidase (MAO) inhibitor\n\uf0af\nincreases levels of serotonin and norepinephrine \nin the brain and periphery\n\uf0af\nincreases the risk of serotonin syndrome in \npatients taking serotonergic drugs\nLinezolid Adverse Effects\n46\nDrug-drug interactions\nAvoid concomitant use with:\n\u2022 Serotonin reuptake inhibitors\n\u2022 Tricyclic antidepressants\n\u2022 Meperidine\n\u2022 Sympathomimetic agents\n\u2022 Vasopressive agents\nDrugs-disease interactions: \n\u2022 Uncontrolled hypertension\n\u2022 Pheochromocytoma\n\u2022 Thyrot..."
    }
  ]
}